secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001297184-22-000026
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q1 2022 revenue $120.4M (+17% YoY); GAAP EPS $0.47 vs $0.10
---------------------------------------------------------------------

- Net revenues $120.4M for Q1 2022, up from $103.0M in Q1 2021 (+17% YoY).
- GAAP net income $24.3M ($0.47 diluted EPS) vs $5.0M ($0.10) a year ago.
- Adjusted non-GAAP net income $24.6M ($0.47 EPS) vs $13.6M ($0.27) in Q1 2021.
- CEO cites strong sales of recent complex product launches; optimistic for continued growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000026/0001297184-22-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718422000026/amph-20220509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-22-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer